Judge blocks Colorado's first-in-the-U.S. Enbrel price cap

Key Facts

At a time of rising political pressure on U.S. drug pricing, the court ruling redraws the line around state intervention in the market. A federal judge blocked Colorado from capping the price of Amgen's Enbrel, a first-of-its-kind move by a U.S. state. The effort was stopped before it could take effect.

The case lands in a broader backdrop of intensified scrutiny on prescription-drug prices, especially blockbuster therapies like Enbrel. In market terms, AMGN closed at $362.12 on June 30, 2026, with an intraday range of $356.87 to $362.78, according to market data. The data set provided does not show direct moves for peers in this package, but the decision removes at least one regulatory overhang for Amgen.

What to watch next is whether the ruling encourages fresh legal challenges to similar state-level pricing efforts. Investors will also be watching for any additional comment from Amgen or Colorado, as well as AMGN's next close versus its recent levels, after it finished the June 30, 2026 session near the top of its daily range.

Version History